Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma.
You may also be interested in...
Draft intellectual property chapter of the Trans-Pacific Partnership includes a provision prohibiting signatories from denying patents solely because a product did not show enhanced efficacy over a known product.
Brand industry hopes weaknesses in Canada’s intellectual property regime, including lack of patent term restoration and a higher patent utility standard for biopharmaceutical products, could be addressed through the 11-nation talks on a Trans-Pacific Partnership agreement.
The nine countries negotiating the free trade agreement disagree on text for the intellectual property chapter; pharma continues to push for 12 years of biologics data exclusivity while generic associations oppose that and other IP proposals.